May 20, 2016 5:20pm

 

Helping sector stocks rise amid a scarcity of news …

 

Pre-open indications: 3 hit and 2 miss

 

Do you care what happened today, you should … because it has implications to Monday's sector activity?  

Subscribe:  http://www.regmedinvestors.com/create-account    

 

 

There are two things that everyone needs,  interpretation and translation of intelligence, not just news or information - we get too much!

  • To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy and regenerative medicine portfolio to track and monitor its pricing metric;

 

 

U.S. stocks closed higher Friday. The Dow failed to recover gains for the week after stocks fell amid renewed concerns of a rate hike sooner rather than later, the NASDAQ rose and the S&P traded up.

The NASDAQ closed UP +57.03 or +1.21% to 4,769.56 and the DOW closed  UP +65.54 or +0.38% to 17,500.94.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.   

  • Opened positive with an A/DL of 25/14 and 4 flats;

 

  • The mid-day stayed positive  with an A/DL of 37/5 with 1 flat;

 

  • The closing bell remained positive  with A/DL of 31/10 with 2 flats

 

 

Today’s Bottom Line:

  • On the basis of my own code of integrity, I have one rule: I eat my own cooking and I own up to my “issues”!  I write every line that investors need to avoid risks as if I was the first to be hurt if I am wrong!

 

 

Henry’omics:

Sector stocks opened positive, stayed positive at the mid-day and closed positive.

  • It’s time to get realistic to the expectations of “our” universe!

These days, investors, whether brokers, small funds or individuals are complaining about what a rough five (5) months it's been, yet there are many a trader who pipes up with a story about how they've made all kinds of money.

  • If you know your numbers, however, you'd know that in 2016, the SCGT&RM sector stocks were down in value, as lofty valuations were cremated.

Another problem and the main one is that the sector is led by a “herd” mentality.

  • It's much easier to get “screwed” doing what everyone else is doing … than to make the tough decision to sell and then buy back in.

But, it’s easier than you think – look at the market for what it is — a voting mechanism for buyers and sellers!

 

 

Pre-open indication batting stats – 3 hit and 2 miss:

  • Cesca Therapeutics (KOOL) closed DOWN -$0.47 – hit;
  • Cellectis SA (CLLS) closed UP +$1.53 – hit;
  • Histogenics (HSGX) closed DOWN -$0.03 – miss;
  • Spark Therapeutics (ONCE) closed UP +$3.67 – miss;
  • Verastem (VSTM) closed UP +$0.06 – hit;

 

 

Out and about:

Cesca Therapeutics (KOOL) closed UP on Thursday +$1.60 to $3.61

  • On the basis of one (1) patient treated;
  • Be ready for a downward SLIDE … and it fell -13.02% or $0.47 to $3.14

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Friday traded 15.5;
  • Thursday traded 16.7;
  • Wednesday traded at 15.3;
  • Tuesday traded below 15;
  • Monday traded below 14.6;
  • Last, Friday closed near 14.5;

 

 

Who was leading the declines – to of the bottom 5?

  • Cesca Therapeutics (KOOL) closed down $0.47 to $3.14;
  • BioLife Solutions (BLFS) -$0.07 to $1.47;
  • Brainstorm (BCLI) -$0.06 to $2.21;
  • uniQure (QURE) -$0.03 to $12.03;
  • Histogenics (HSGX) closed down -$0.03 to $1.81

 

 

Who was UP – top 5:

  • Spark Therapeutics (ONCE) closed up +$3.67 to $50.84;
  • bluebird bio (BLUE) -$1.77 to $40.60;
  • Cellectis SA (CLLS) +$1.53 to $30.78;
  • Kite Pharma (KITE) +$1.52 to $47.00;
  • Intrexon (XON) closed up +$1.52 to $28.05

 

 

Who was flat?

  • ReNeuron (RENE.L) at $3.375;

 

 

Most active sector stocks + and -:

  • Cesca Therapeutics (KOOL) -13.02%;
  • BioLife Solutions (BLFS) -4.28%;
  • Brainstorm (BCLI) -2.64%;
  • Neuralstem (CUR)-1.84%;
  • Histogenics (HSGX) -1.63%;

versus …

  • Stemline (STML) +16.09%;
  • StemCells (STEM) +10.11%;
  • BioTime (NYSEMKT: BTX) +9.56%;
  • Spark Therapeutics (ONCE) +7.78%;
  • Biostage (BSTG) +7.09%

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.